Genesis Bioventures Announces Restructuring Management Agreement
News Nov 11, 2005
Experigen's founder, Douglas C. Lane, an executive with over 30 years experience in pharmaceutical, biotechnology, diagnostics and technology companies, will work closely with GBI's board of directors and officers to develop and execute the plan.
“Mr. Lane's management of business development and mergers and acquisitions at SmithKline Beecham (now GlaxoSmithKline), his interim board experience at Human Genome Sciences, the IPO development at Hyseq Corporation (now Nuvelo) and his recent leadership at the ViaSpace company, ViaLogy Corp., is an excellent fit with our breast cancer diagnostics company and our prion disease rapid assay company,” said Mr. McCartney, Chairman and CEO of Genesis Bioventures.
“We are very pleased to have Mr. Lane lead our growth initiatives.”
“Genesis Bioventures is an undiscovered company with unique growth opportunities,” Mr. Lane said.
“I am looking forward to working with Mr. McCartney, the board and management to create strong value for the Company and its shareholders.”
“There is an outstanding opportunity in GBI and its portfolio companies, with very good science and highly motivated and dedicated management and employees, all prerequisites to success.”
Two proteins that activate the fastest molecule in our nerve cells have been identified by researchers at University of Warwick. This mechanism is responsible for transport through our nervous system. This finding could lead to a new therapeutic treatments for people with hereditary spastic paraplegia and other neurological disorders.READ MORE